Citicoline (CDP-choline) does not have adequate trials as an ADHD treatment. Attention-test findings are a different question.
Sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately.
There is no good evidence citicoline treats ADHD. That is the headline, and it is not softened by nearby marketing.
Separate small trials reported attention and psychomotor findings in other groups. One was in women and one was in adolescent males. Both were funded by the maker of Cognizin. A change on an attention test in a small industry-funded study is not evidence that citicoline treats ADHD.
If attention or ADHD is the concern, the person to ask is the clinician who already knows the history. Questions for that visit are listed on their own page.
| Question | Best evidence | Tier | Bottom line |
|---|---|---|---|
| ADHD treatment | No adequate trials | , | There is no good evidence citicoline treats ADHD |
| Attention tests | McGlade trials, Cognizin-funded | T1 (small) | Small, industry-funded attention findings, not an ADHD treatment trial |
This site covers a compound with a long research history. Citicoline (CDP-choline) has been tested in stroke, brain injury, age-related memory complaints, glaucoma, and healthy-attention studies. Against that backdrop, the ADHD page is deliberately brief. It says one thing: there is no good evidence citicoline treats ADHD.
That sentence is not hedging. It is not "more research is needed" as a polite exit. It is a statement that adequate treatment trials in ADHD do not exist. Nothing in the research record comes close to filling that gap. The sections below explain why the nearby findings do not change that conclusion, and how to read the attention studies that marketing tends to quote.
A treatment trial for ADHD needs specific features. It needs participants who actually have ADHD, diagnosed by a recognised method. It needs a placebo or active comparison group. It needs validated outcome measures for symptoms, not just laboratory task scores. It needs enough people and enough time for a real treatment effect to show up if one exists.
Citicoline does not have a trial with that shape. No adequate study has randomised people with ADHD to citicoline or placebo and measured whether symptoms improved. That is the entire basis for this page's bottom line, and it is the same bottom line regardless of what the ingredient label on a bottle suggests.
This matters because ADHD is a condition with established treatments. Stimulant and non-stimulant medications, behavioural interventions, and school or workplace supports all have evidence bases of varying strength. A supplement with no adequate treatment trial is not in that conversation, and presenting it as if it were would mislead people making real decisions.
Two small trials are the source of most attention-related marketing claims, so they deserve a careful description.
One trial enrolled adult women and tested citicoline at 250 mg and 500 mg per day. It reported better scores on attention testing in the citicoline groups compared with placebo. The other trial enrolled adolescent males and reported gains on attention and psychomotor speed measures.
Three facts limit what these trials can tell anyone with ADHD. First, neither trial enrolled people with ADHD. The participants were not patients with a diagnosis; they were research volunteers in small studies of attention performance. Scoring differently on a computerised attention task is not the same thing as having a treated condition.
Second, both trials were small. Small studies can detect large effects and miss everything else, and their results are fragile. A single modest-sized follow-up can overturn them.
Third, both trials were funded by the maker of Cognizin, a brand of citicoline. Industry funding does not make a result false, but it raises the standard of confirmation required before the result should guide decisions. Independent replication is the usual test, and it has not happened for these attention findings.
None of this is an argument that the trial teams did poor work. It is an argument about scope. An attention-test change in a small, funded, non-ADHD sample answers a narrow question. ADHD treatment is a different and much larger question.
Marketing copy often blurs these two words, and the blur does real harm. Attention is a cognitive function anyone can measure on a task. ADHD is a clinical diagnosis that involves patterns of inattention, hyperactivity, and impulsivity that impair daily life, usually beginning in childhood, assessed over time and across settings.
Many things can shift an attention-task score on a given day: sleep, caffeine, anxiety, practice effects, the room temperature. A single-task improvement in a short study does not translate into better functioning at school or work, fewer symptoms on a rating scale, or any of the outcomes that matter to a person with ADHD. This is why regulatory and clinical standards for ADHD treatments demand symptom-based endpoints in diagnosed patients, not laboratory task scores in volunteers.
The same caution applies in reverse. The fact that citicoline's attention trials were not ADHD trials is not a technicality to wave past. It is the central reason the evidence cannot support the claim that citicoline treats ADHD.
Readers sometimes arrive at this page from the site's other evidence summaries and wonder whether findings there rescue the ADHD case. They do not, and it helps to see why.
The largest stroke trial, ICTUS, randomised about 2,300 people and found no improvement in 90-day recovery versus placebo. Earlier meta-analyses had suggested benefit; the largest trial did not confirm it. The COBRIT trial in traumatic brain injury found no improvement in functional or cognitive outcomes versus placebo. For chronic cerebrovascular cognitive decline, a Cochrane review reported modest short-term benefit on memory and behaviour, but the trials were short and low quality. An observational study in mild vascular cognitive impairment, IDEALE, associated citicoline use with stable scores versus decline in an untreated group, and observational designs cannot prove cause. Small glaucoma trials reported changes on electrophysiological measures, with the effect on vision loss not established.
Notice the pattern: even in conditions with far more research than ADHD, the strongest signals are modest, contested, or contradicted by larger trials. ADHD has none of this scaffolding. If citicoline's best-studied conditions produce results this mixed, there is no route by which an untested condition ends up with a stronger claim.
The honest summary of the whole record is available on the citicoline evidence, condition by condition page, and the negative trials sit alongside the positive ones there.
If you or your child has attention difficulties, the first step is evaluation, not supplementation. Attention problems have many causes, and ADHD is only one of them. Sleep disorders, anxiety, depression, learning differences, thyroid problems, and iron deficiency can all look similar from the outside. A clinician who takes a proper history can sort these apart in a way no supplement label can.
If ADHD is diagnosed, evidence-based treatments exist and should be the starting point. Do not stop or reduce a prescribed ADHD medicine because of anything on a supplement page. Do not substitute an untested supplement for a treatment with an actual evidence base.
If you are weighing citicoline for general attention support without a diagnosis, be clear about what you would be relying on: two small, industry-funded studies that did not involve people with ADHD. That is a thin basis for an expectation. The questions to ask your doctor page offers a structure for that conversation, and the side effects and doses used in studies pages cover tolerability. In trials, citicoline was generally well tolerated at 250, 2,000 mg per day, with mild gastrointestinal upset, headache, and insomnia the most common complaints. Pregnancy and breastfeeding data are lacking.
One interaction deserves a note for a specific group: citicoline may enhance levodopa effects, so people with Parkinson's disease should involve their neurologist before taking it.
Much of the marketing aimed at attention concerns is really aimed at parents. That targeting is worth resisting. The adolescent attention trial cited in marketing involved adolescent males without ADHD, was small, and was funded by the brand's maker. It cannot tell a parent whether citicoline will help a child who is struggling in class.
Decisions about a child's attention, behaviour, or school performance belong with that child's clinician. If cost or access is a barrier to evaluation, raising that openly with a paediatrician or school team is more likely to produce a useful plan than a supplement purchase. This site does not recommend products on evidence pages, and this page is no exception.
Sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately.
Every cognition-related page on this site carries that line. Attention complaints are not emergencies, but some readers arrive here while researching memory or thinking changes in themselves or an older relative, and sudden symptoms of that kind need emergency care, not a supplement.
There is no good evidence that it does.
Small industry-funded trials reported attention-test changes. They were not adequate ADHD treatment trials.
No. Do not change a prescription because of a supplement page.
It states the evidence gap. Decisions about a child belong with that child's clinician.
Side effects and the doses used in studies each have a page, linked above.
Cognition pages on this site include the emergency line for sudden stroke symptoms.
This site reports what studies found. It does not choose a dose for you.